Patients with residual disease and breast cancers with a triple-negative subtype in the CREATE-X trial [12] and HER2-positive subtype in the KATHERINE trial [13] were shown to have improved OS and DFS outcomes with added adjuvant regimens. This evidence concerns the gene ERBB2 and breast carcinoma.